CION Ameerpet
If you or a loved one has glioblastoma, the MGMT methylation result from the biopsy helps predict how well chemotherapy is likely to work. We explain what it means in plain language — and review it for you.
If you are reading a glioblastoma (GBM) biopsy report, you may have seen the words "MGMT promoter methylated" or "unmethylated." It can feel like another piece of jargon at an overwhelming time. In plain language, this single result helps your team predict how well chemotherapy is likely to work — which is why it matters so much.
MGMT stands for O6-methylguanine-DNA methyltransferase. It is a gene that makes a DNA-repair enzyme. That enzyme repairs exactly the kind of DNA damage that alkylating chemotherapy — the standard chemotherapy used alongside radiation for glioblastoma — is designed to cause. So the amount of this enzyme a tumour makes affects how vulnerable it is to treatment.
When the MGMT promoter (the "on switch" for the gene) is methylated, the gene is partly switched off. The tumour makes less repair enzyme, the chemotherapy damage stays in place, and the tumour tends to respond better. When the promoter is unmethylated, the gene stays active, the tumour repairs the chemotherapy damage more efficiently, and it tends to resist the drug more. This is the heart of why the test is part of every glioblastoma's molecular testing workup at CION.
MGMT promoter methylation is recognised by both NCCN (National Comprehensive Cancer Network) and EANO (European Association of Neuro-Oncology) glioma guidelines as the strongest tissue-based predictor of how an individual glioblastoma will respond to alkylating chemotherapy given with radiation. The marker first reached worldwide attention through the landmark Hegi study (New England Journal of Medicine, 2005), which reported that methylated tumours benefited more from adding chemotherapy to radiation than unmethylated tumours did.
Your MGMT result does not decide on its own whether you receive treatment. It shapes the conversation about how much benefit chemotherapy is likely to add — always read alongside your IDH status, age, fitness, and how much tumour was safely removed.
The repair gene is partly switched off, so the tumour makes less repair enzyme. It is more sensitive to alkylating chemotherapy. In published series reported by NCCN and EANO, methylated tumours are associated with a better response to standard chemoradiation and longer survival. This is generally the more reassuring result — though it is one factor among several, never a guarantee.
The repair gene stays active, so the tumour repairs chemotherapy damage more efficiently and tends to resist alkylating chemotherapy more. This does not mean treatment will not help — many fit adults still benefit, and guidelines usually still recommend chemoradiation. It does mean your team weighs the expected benefit more carefully, especially in older or frailer patients, and may discuss clinical-trial options.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
MGMT, IDH, grade, methylated, unmethylated — it is a lot to take in. CION's neuro-oncology team will walk through your report with you, in plain language, across our Hyderabad centres.
The test is done on the tumour tissue itself — the same sample taken during surgery or a stereotactic biopsy. If you have already had surgery, no extra procedure is needed; the existing tissue block can be sent for testing.
At CION, biopsy and any tumour-removal surgery are coordinated with accredited neurosurgical partners. The tissue obtained is sent to pathology for both standard microscopic analysis and molecular testing. CION delivers the medical (systemic) and radiation parts of glioblastoma care directly.
The laboratory examines the MGMT promoter region using a validated methylation assay — commonly methylation-specific PCR (MSP) or pyrosequencing. These tests detect whether the promoter is chemically methylated. The tumour is then reported as methylated or unmethylated. Results usually take several working days.
MGMT status is never read in isolation. It is interpreted with IDH status and the other markers from the WHO 2021 framework, your age, your performance status, and how much tumour was safely removed. CION reviews every result at a multidisciplinary tumour board for every patient before finalising a plan.
Already have a report? If it does not mention MGMT status, ask before treatment begins. Send it to CION for a free review — we can advise whether the existing tissue block can still be tested.
MGMT methylation informs several decisions in glioblastoma care. Here is how it fits into each part of the pathway — always alongside age, fitness, IDH status and extent of resection, and always per NCCN and EANO guidance.
For most medically fit adults with newly diagnosed glioblastoma, NCCN and EANO recommend radiation therapy with concurrent alkylating chemotherapy followed by further chemotherapy — regardless of MGMT status. The reason is that some unmethylated tumours still respond, so withholding chemotherapy purely on the basis of an unmethylated result is not recommended in this group. MGMT status here informs the discussion about the expected size of benefit and helps set realistic expectations, rather than deciding whether treatment is given at all.
In older adults and those who are less fit, MGMT status carries more weight in the decision. Guidelines support tailoring treatment by MGMT methylation in this group. A methylated result may favour a chemotherapy-containing approach, including shorter ("hypofractionated") radiation schedules combined with chemotherapy. An unmethylated result may shift the discussion toward a radiation-focused approach or a clinical trial, balancing likely benefit against side effects and quality of life. These are individualised decisions made by the neuro-oncology team with you and your family.
Glioblastoma has no single survival number — outcomes vary widely and depend on many factors. What published guidelines and studies (NCCN, EANO) consistently show is that, as a group, patients with methylated tumours treated with standard chemoradiation tend to do better than those with unmethylated tumours. This is reported as ranges across populations, never as a promise for any one person. Knowing your MGMT status helps your team have an honest, compassionate conversation about what to expect — so decisions are made with clear information, not guesswork.
Many glioblastoma clinical trials use MGMT status as an entry criterion or to interpret results, because the marker so strongly affects chemotherapy response. If your tumour is unmethylated and the expected benefit of standard chemotherapy is more limited, a trial of a newer approach may be a reasonable option to discuss. CION's tumour board can advise whether a trial pathway is appropriate and help with referral where relevant.
MGMT status is usually measured once at diagnosis and used to guide first-line treatment. When a glioblastoma recurs, the biology can shift, and a repeat biopsy is sometimes considered to re-check molecular markers before choosing further treatment. Whether re-testing adds value is decided case by case. At recurrence, CION's tumour board reviews your full history — including the original MGMT result — to recommend the next step, which may include further systemic therapy, re-irradiation in selected cases, or a clinical trial.
CION delivers the medical (systemic) therapy and radiation therapy for glioblastoma directly, along with steroid and seizure management, imaging, molecular testing arrangement, and supportive and rehabilitation care. Any neurosurgery — biopsy, tumour removal, or related procedures — is coordinated with accredited neurosurgical partners. Every glioblastoma case is reviewed by a multidisciplinary tumour board so that surgery, radiation and medical oncology are aligned from the start. You can explore the full pathway on our brain tumour treatment in Hyderabad page.
MGMT status does not predict response to every treatment — only to alkylating chemotherapy. Radiation therapy benefit is not determined by MGMT methylation. This is why your team always reads MGMT alongside your IDH status and the wider WHO 2021 molecular picture, rather than treating any single marker as the whole answer.
A second opinion is especially worthwhile for glioblastoma in a few situations. You deserve to feel confident before treatment begins:
CION offers a free written second opinion reviewed by a neuro-oncology tumour board. Share your MRI, biopsy and any molecular results — or call 18002028726 — and we will explain what your MGMT methylation status means for the road ahead.
If your glioblastoma biopsy report does not mention MGMT methylation, ask before treatment begins. Get a free written second opinion from CION's neuro-oncology tumour board.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.MGMT is a DNA-repair gene. O6-methylguanine-DNA methyltransferase is the enzyme it makes — it repairs the DNA damage that alkylating chemotherapy is designed to cause. When the MGMT promoter is "methylated" (chemically switched off), the tumour makes less of this repair enzyme, so the chemotherapy works better. Pathologists test the biopsy tissue to report the tumour as MGMT-methylated or unmethylated. This single result helps your team predict how well alkylating chemotherapy is likely to work and set realistic expectations — which is why molecular testing is now part of the standard biopsy workup at CION.
Alkylating chemotherapy works by adding damaging chemical groups to tumour DNA. The MGMT enzyme undoes exactly that damage. If a tumour is MGMT-methylated, it produces little of this enzyme, so the chemotherapy damage stays — and the tumour is more sensitive to treatment. If the tumour is unmethylated, it actively repairs the damage and resists the drug more. Per NCCN and EANO guidance, MGMT status is the strongest tissue predictor of how an individual glioblastoma responds to alkylating chemotherapy given alongside radiation. It does not change whether you receive treatment — it informs the conversation about benefit and intensity.
A methylated MGMT promoter is generally the more favourable result — these tumours tend to respond better to alkylating chemotherapy and, in published series reported by NCCN and EANO, are associated with longer survival on standard chemoradiation. An unmethylated result does not mean treatment will not help; it means your team weighs the expected benefit of chemotherapy more carefully, especially in older patients. MGMT status is one important piece — your glioblastoma plan also depends on age, how much tumour was safely removed, your general fitness, and other molecular markers. CION reviews every result at a tumour board, not in isolation.
Testing is done on the tumour tissue obtained at surgery or stereotactic biopsy — no extra procedure is needed if you have already had surgery. The pathology laboratory examines the MGMT promoter region using validated methylation assays (such as methylation-specific PCR or pyrosequencing) and reports the tumour as methylated or unmethylated. At CION we arrange MGMT testing — together with IDH and other markers — as standard on biopsy samples from malignant gliomas. Results typically take several working days. If you already have a biopsy report without MGMT status, bring it to your consultation and we can advise whether the existing block can be sent for testing.
Not by itself. For most fit adults with glioblastoma, NCCN and EANO still recommend chemoradiation regardless of MGMT status, because some unmethylated tumours do respond. The result becomes most useful in specific decisions — for example, in elderly or frail patients, where guidelines support tailoring treatment by MGMT status, an unmethylated result may shift the discussion toward radiation-focused approaches or clinical trials. These are nuanced decisions made by your neuro-oncology team, weighing benefit against side effects. The right answer is personal, and a second opinion can help you feel confident about the plan.
MGMT status is usually treated as a fixed feature of the tumour measured at diagnosis, and it guides the initial plan. However, when a glioblastoma recurs, the biology can shift, and a repeat biopsy is sometimes considered to re-check molecular markers before choosing further treatment. This is decided case by case. What matters most is that the test was done correctly at diagnosis and interpreted alongside the full picture. If your tumour recurs, CION's tumour board reviews whether re-testing or a clinical-trial option is appropriate for your situation.
Yes. CION arranges MGMT and IDH molecular testing as standard on malignant glioma biopsies and delivers the medical (systemic) and radiation parts of glioblastoma care directly — including alkylating chemotherapy alongside radiation, steroid and seizure management, and supportive care. Neurosurgery, including any biopsy or resection, is coordinated with accredited neurosurgical partners. Every case is reviewed by a multidisciplinary tumour board. You can discuss your brain tumour treatment options across our Hyderabad centres. Call or request a free 45-minute consultation.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.